Orange Biomed

Our Co-Founders Yeaseul Park and Dr. Unghyeon Ko were featured in BioSpectrum Asia’s special #WorldDiabetesDay report discussing digital innovations advancing diabetes care: bit.ly/4fWBnhY Digital health tools, such as portable A1C tests, are transforming diabetes management, allowing patients to better manage their conditions outside of hospitals. Park shared with BioSpectrum, “Previously, patients had limited information about their condition, which led to anxiety and a lack of motivation for managing it. Now, with tools like CGMs, personal A1C monitors, and mobile apps, patients can check their levels anytime, anywhere, and easily access professional support through mobile platforms.” A1C testing is an essential marker for long-term diabetes management, but there are challenges in ensuring accuracy in home-based devices. Orange Biomed is applying microfluidic technology to advance A1C testing to help overcome these challenges by providing patients with lab-accurate results. Learn more about our award-winning solution, OBM rapid A1c here: bit.ly/4f6fmwQ #BioSpectrum #DiabetesAwareness #MicrofluidicTechnology #A1CTesting #HealthTech #DiabetesInnovation #HealthcareRevolution #OrangeBiomed #Diabetes #DiabetesCare #Microfluidics #MicrofluidicDevices #DiabetesResearch 

Today is World Diabetes Day. World Diabetes Day was established in 1991 by the International Diabetes Federation (IDF) and the World Health Organization (WHO) and became an official United Nations Day in 2006. Despite advances in treatment, millions of people with diabetes still face daily challenges impacting their physical and mental well-being. Did you know? ● 36% of people with diabetes experience significant diabetes distress. ● 63% fear complications affecting their well-being. ● 28% struggle to maintain a positive outlook. Read more about World Diabetes Day: bit.ly/4hL5qLd Orange Biomed is committed to making a difference. Our focus is on developing innovative solutions that help overcome the gaps in diabetes management and reduce the risk of diabetic complications. At the last day of #MEDICA2024, coinciding with World Diabetes Day, we educated audiences about critical gaps in diabetes management, including testing accuracy across diverse populations and how our novel technology application helps overcome these challenges: bit.ly/4hHyS4X OBM rapid A1c is designed to provide accurate readings regardless of hemoglobin variants, which can affect results in traditional A1C testing methods, particularly for certain ethnic groups. Check out our recent news to learn more about how Orange Biomed is revolutionizing diabetes care management: bit.ly/3O6w4kj #WorldDiabetesDay #DiabetesAwareness #DiabetesAwarenessMonth #MEDICA #OrangeBiomed #A1C #KnowYourA1C #CheckYourA1C #A1CAwareness

#MEDICA2024 kicks off on Monday! Stop by Hall 13 / D77-10 to preview Orange Biomed’s breakthrough diabetes testing method in person: https://bit.ly/3NHBp19 This year, featured in MEDICA’s Start-Up Park, Orange Biomed will showcase the world’s first pocket-sized, microfluidic-based A1C analysis device: OBM rapid A1c. November is not only the start of MEDICA, but also #DiabetesAwarenessMonth. We look forward to showcasing our solution at the show during this pivotal month and demonstrating how our novel approach to A1C testing could potentially transform diabetes monitoring for people of all backgrounds. Visit Orange Biomed from November 11-14 at MEDICA in Düsseldorf, Germany, and reach out to our team to book a media interview or meeting: shannon@orangebiomed.com #MEDICA #DiabetesAwareness #MicrofluidicTechnology #A1CTesting #HealthTech #DiabetesInnovation #HealthcareRevolution #OrangeBiomed #Diabetes #DiabetesCare #Microfluidics #MicrofluidicDevices #DiabetesResearch

Orange Biomed will be presenting at #MEDICA2024 this November! Learn more about our novel technology application for healthcare: bit.ly/4fmnB8c This year, MEDICA is taking place during both #DiabetesAwarenessMonth and #WorldDiabetesDay. In honor of these observances, Orange Biomed will educate attendees on the critical gaps in diabetes care management and testing accuracy across diverse populations and how we aim to provide a more inclusive, affordable, and accessible solution. This portable, lab-accurate device uses a groundbreaking microfluidic approach that represents a significant departure from traditional testing methods. “This innovation is designed to provide consistent readings regardless of hemoglobin variants, which can affect results in traditional testing methods, particularly for certain ethnic groups” said Orange Biomed CEO Yeaseul Park Attendees are invited to visit Orange Biomed and preview the OBM rapid A1c meter at MEDICA, the largest medical trade fair in the world, held in Düsseldorf, Germany, from November 11-14, 2024, in Hall 13 / D77-10: https://bit.ly/3NHBp19 #MEDICA #DiabetesAwareness #MicrofluidicTechnology #A1CTesting #HealthTech #DiabetesInnovation #HealthcareRevolution #OrangeBiomed #Diabetes #DiabetesCare #Microfluidics #MicrofluidicDevices #DiabetesResearch

Did you know that more than 1 in 5 people with diabetes do not know they have it, putting them at high risk for health complications? Find out how Orange Biomed is revolutionizing A1C monitoring in our research abstract: bit.ly/4e77TNg While traditional A1C meters have limited accessibility and require precise sample volume and temperature-sensitive maintenance, this method of A1C monitoring can improve diabetes management. Our study, published by the Journal of the American Diabetes Association, details Orange Biomed’s breakthrough testing method, which is easy to use and can be free from sampling error. By employing a novel microfluidic channel, this system demonstrates the potential RBC deformability-based A1C tests have to change the A1C testing landscape and provide patients with a more accurate and accessible testing option. Learn more about our diabetes testing and management solution here: bit.ly/4f6fmwQ #MicrofluidicTechnology #A1CTesting #DiabetesInnovation #HealthcareRevolution #OrangeBiomed #Diabetes #DiabetesCare #TechnologyNews #Microfluidics #MicrofluidicDevices #ADA #AmericanDiabetesAssocation #DiabetesResearch

How are microfluidic devices producing rapid, sensitive, and portable POC detection of bio-analytes and disease biomarkers? Find out here: bit.ly/4gI767K This review paper, led by the Departments of Mechanical Engineering and Chemical Engineering at the Indian Institute Of Technology, Kanpur, and the Faculty of Mechanical Engineering at the Technion - Israel Institute of Technology, explores how integrated microfluidic devices can enhance disease identification and management in point-of-care (POC) diagnostics by providing an interdisciplinary perspective on modern diagnostics. Thank you Prateechee Padma Behera, Natish Kumar, Monika Kumari, Sumit Kumar, Ph.D., Pranab Mondal, and Ravi Kumar Arun for your insights on microfluidic devices. At Orange Biomed, we’re committed to sharing influential studies and reviews on microfluidic technology’s impact. The examples highlighted in this review demonstrate how the miniaturization of diagnostic methods onto microfluidic chips can effectively reduce sample volumes and enhance portability. Orange Biomed’s microfluidic approach is built on principles uniquely enabled by microfluidics, rather than adapting traditional lab methods or chromatographic techniques. We have developed capillary-scale microfluidic channels designed to physically measure red blood cell stiffness—offering a completely novel approach to using microfluidic chips for diagnostics. Learn how Orange Biomed is using microfluidic technology to provide lab-accurate A1C test results: bit.ly/4f6fmwQ #MicrofluidicTechnology #A1CTesting #DiabetesInnovation #HealthcareRevolution #OrangeBiomed #Diabetes #DiabetesCare #TechnologyNews #Microfluidics #MicrofluidicDevices

Today is the last day of the #DiabetesTechnologyMeeting. Thank you Diabetes Technology Society (DTS) for an incredible experience! Orange Biomed was honored to present our research abstract, ”Implementing a stiffness measurement of red blood cells to predict HbA1c”, and our innovative A1C testing solution during the Startup Showcase! Thank you to Kelly Close, George Cembrowski, MD, PhD, Mark Tapsak, and more for attending our presentations and learning about OBM rapid A1c. It was extremely valuable to discuss the future of diabetes management with diabetes industry leaders. Orange Biomed also enjoyed our lunch discussion with Ny'Nika McFadden, PhD, Bronwyn Harris, and Jessie Juusola, PhD, who shared their knowledge about clinical trials, challenges faced by diabetic college students, and measuring for health outcomes Didn't attend DTM? DM our team to set up a meeting or email shannon@orangebiomed.com #DiabetesTechnology #DiabetesTech #DiabetesTechnologySociety #A1C #A1CTesting #MicrofluidicTechnology #DiabetesTechnologyMeeting #DTM2024

It’s Day 2 of the #DiabetesTechnologyMeeting! Thank you to everyone who attended Orange Biomed’s abstract presentation last night; we were pleased to connect with Nada Haboudal, Timothy Bailey, Muhammad Mujeeb-U-Rahman, and others to showcase our innovative A1C testing method. Our abstract presentation offered a detailed overview of the microfluidic components of OBM rapid A1c, discussing their capabilities in improving traditional test methods. Today, our team attended David Kerr MD’s presentation on Nutrition Monitoring for Diabetes which discussed how there are large variations across individuals and highlighted the importance of accurate testing solutions. We also heard from Anthony Maiorana, who shared the FDA’s current views and regulatory approaches for assessing new technologies and innovative devices. Missed our presentation yesterday? Visit the Startup Showcase tonight from 5:00-7:00 p.m. to see the world’s first microfluidic-based A1C test in person. Tomorrow is the last day of DTM! Don't miss the chance to meet our team and learn more about our new breakthrough method of testing A1C. Reach out to our team to book a media interview or meeting (in-person or virtual): shannon@orangebiomed.com #DiabetesTechnology #DiabetesTech #DiabetesTechnologySociety #A1C #A1CTesting #MicrofluidicTechnology #DiabetesTechnologyMeeting #DTM24

Orange Biomed is having a blast in Burlingame at the #DiabetesTechnologyMeeting! At 4:30 p.m. this afternoon, Orange Biomed is presenting our research abstract poster presentation, “Implementing a stiffness measurement of red blood cells to predict HbA1c”, which will showcase how OBM rapid A1c uses microfluidic technology to provide lab-accurate A1C results in point-of-care and at-home testing settings. Stop by slot number 27 to learn more! It’s been great connecting with fellow diabetes advocates, including David Klonoff, Jane Seley, Joe Wang, Stefan Pleus, Muhannad Alkilani, Guido Freckmann, and Irina Nayberg. Looking forward to connecting with more industry leaders over the next 2 days! Orange Biomed Engineering Director Dr. Eunyoung Park also connected with Jeremy Alkire of Close Concerns, showing him OBM rapid A1c, which is currently undergoing clinical trials in CA, and explained how the portable, durable, and reusable device can last a lifetime. Orange Biomed attended an insightful presentation, led by Mark Clements, MD PhD CPI FAAP, about remote patient monitoring and developing a smart system for diabetes management and treatment. He highlighted that Children's Mercy Kansas City has developed a population health platform, including data aggregation and processing with dashboards, in partnership with Stanford University. We also heard from Ali Cinar, of the Illinois Institute of Technology, who presented the state of AI used in diabetes technology, including its benefits and challenges. Our team looks forward to attending more presentations throughout the rest of Day 1 and over the next two days. Can't make it to our presentation tonight? Stop by the Startup Showcase tomorrow from 5:00-7:00 p.m. to see how our breakthrough application of microfluidic technology for A1C testing works in person. Reach out to our team to book a media interview or meeting (in-person or virtual): shannon@orangebiomed.com #DiabetesTechnology #DiabetesTech #DiabetesTechnologySociety #A1C #A1CTesting #MicrofluidicTechnology #DiabetesTechnologyMeeting #DTM #OrangeBiomed #DTM2024

The 2024 Diabetes Technology Meeting is less than a week away! Orange Biomed is excited to participate in this year's Startup Showcase, where we will present “Implementing a stiffness measurement of red blood cells to predict HbA1c.” Learn more at Poster #27, on October 15th at 4:30 PM: https://bit.ly/4efjhHJ Our Startup Showcase presentation on Wednesday, October 16th (5:00-7:00 PM) will focus on how the microfluidic technology application in our breakthrough diabetes testing solution, OBM rapid A1c, is redefining diabetes management. The OBM rapid A1c is the first portable and reusable A1C testing system, agnostic to hemoglobin variants, delivering rapid, lab-accurate A1C results from one drop of blood. Reach out to our team to book a media interview or meeting around DTM: shannon@orangebiomed.com #DiabetesTechnology #DiabetesTech #DiabetesTechnologySociety #A1C #A1CTesting #MicrofluidicTechnology #DiabetesTechnologyMeeting